Cargando…

A Non-invasive Radiomic Method Using (18)F-FDG PET Predicts Isocitrate Dehydrogenase Genotype and Prognosis in Patients With Glioma

Purpose: We aimed to analyze (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) images via the radiomic method to develop a model and validate the potential value of features reflecting glioma metabolism for predicting isocitrate dehydrogenase (IDH) genotype and prognosis. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Longfei, Mu, Wei, Wang, Yaning, Liu, Zhenyu, Liu, Zehua, Wang, Yu, Ma, Wenbin, Kong, Ziren, Wang, Shuo, Zhou, Xuezhi, Wei, Wei, Cheng, Xin, Lin, Yusong, Tian, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6869373/
https://www.ncbi.nlm.nih.gov/pubmed/31803608
http://dx.doi.org/10.3389/fonc.2019.01183
Descripción
Sumario:Purpose: We aimed to analyze (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) images via the radiomic method to develop a model and validate the potential value of features reflecting glioma metabolism for predicting isocitrate dehydrogenase (IDH) genotype and prognosis. Methods: PET images of 127 patients were retrospectively analyzed. A series of quantitative features reflecting the metabolic heterogeneity of the tumors were extracted, and a radiomic signature was generated using the support vector machine method. A combined model that included clinical characteristics and the radiomic signature was then constructed by multivariate logistic regression to predict the IDH genotype status, and the model was evaluated and verified by receiver operating characteristic (ROC) curves and calibration curves. Finally, Kaplan-Meier curves and log-rank tests were used to analyze overall survival (OS) according to the predicted result. Results: The generated radiomic signature was significantly associated with IDH genotype (p < 0.05) and could achieve large areas under the ROC curve of 0.911 and 0.900 on the training and validation cohorts, respectively, with the incorporation of age and type of tumor metabolism. The good agreement of the calibration curves in the validation cohort further validated the efficacy of the constructed model. Moreover, the predicted results showed a significant difference in OS between high- and low-risk groups (p < 0.001). Conclusions: Our results indicate that the (18)F-FDG metabolism-related features could effectively predict the IDH genotype of gliomas and stratify the OS of patients with different prognoses.